Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled for September 14-16, 2026, in New York City. The fireside chat will be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website.
This appearance is significant for investors and the mental health industry because Helus Pharma is advancing HLP003, a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which may expedite its development and review. The company is also developing HLP004, another NSA in Phase 2 for generalized anxiety disorder. These programs address a large unmet need for patients suffering from depression and anxiety, where current treatments often have limited efficacy or delayed onset of action.
Helus Pharma, which operates as the commercial name of Cybin Inc. (founded in 2019), focuses on synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. This mechanism aims to provide durable improvements in mental health, potentially differentiating its products from existing antidepressants. The company’s pipeline includes an extensive research portfolio of investigational NSAs, indicating a broad commitment to addressing mental health conditions.
The H.C. Wainwright conference is a key event for the investment community, and Helus Pharma’s participation offers a platform to showcase its clinical data and strategic vision. Investors will likely watch for updates on HLP003’s Phase 3 trials, which could significantly impact the company’s valuation and the treatment landscape for MDD. With Breakthrough Therapy Designation, HLP003 has the potential to become a first-in-class adjunctive therapy, offering new hope for patients who do not respond adequately to standard treatments.
The company operates in Canada, the United States, the United Kingdom, and Ireland, and has a global reach in its clinical development efforts. For more details, the full press release can be accessed at https://ibn.fm/1HSIo. Additionally, the latest news and updates on HELP are available in the company’s newsroom at https://ibn.fm/HELP.
As the conference approaches, stakeholders will be keen to hear Halstead’s insights on the company’s progress and future milestones. The live webcast and replay provide accessible opportunities for investors to gain a deeper understanding of Helus Pharma’s strategy and the potential of its NSA platform. This engagement underscores the company’s commitment to transparency and its position as a key player in the evolving mental health therapeutics market.
